A 12-Month Prospective,Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern Asia

Abstract

Objectives: This prospective, observational, non-randomized study aimed to describe the relationship between treatment regimen prescribed and the quality of life (QoL) of ADHD patients in countries of Central and Eastern Europe (CEE) and Eastern Asia over 12 months. Methods: 977 Male and female patients aged 6-17 years seeking treatment for symptoms of ADHD were assessed using the Child and Adolescent Symptom Inventory-4 Parent Checklists, and the Clinical Global Impressions-ADHD-Severity scale. QoL was assessed using the Child Health and Illness Profile-Child Edition parent report form. Patients were grouped according to whether they were prescribed psycho- and/or pharmacotherapy (treatment) or not (no/‘other’ treatment). Results: No statistically significant differences were observed between cohorts (treatment vs. no/‘other’ treatment) in terms of change in QoL, although there was improvement over 12 months, with a greater improvement experienced by patients in the treatment cohort in both study regions (CEE and Eastern Asia). Psychoeducation/counselling and methylphenidate were the predominant ADHD treatments prescribed. Conclusions: Although both treatment and no/‘other’ treatment cohorts showed improvements in mean QoL over 12 months, the difference was small and not statistically significant. A major limitation was the higher than anticipated number of patients switching treatments, predominantly from the no/‘other’ treatment cohort.

Keywords

attention deficit hyperactivity disorder quality of life observational study

Get full access to this article

View all access options for this article.

References

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (text rev.). Washington, DC: Author.

Aras

Varol Tas

Unlu

(2007). Medication prescribing practices in a child and adolescent psychiatry outpatient clinic. Child: Care, Health and Development, 33, 482-490.

Bangs

M. E.

Hazell

Danckaerts

Hoare

Coghill

D. R.

Wehmeier

P. M.

. . . Levine

(2008). Atomoxetine ADHD/ODD study group: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics, 121, e314-e320.

Barkley

R. A.

(1998). Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York, NY: Guildford.

Biederman

Mick

Faraone

S. V.

Braaten

Doyle

Spencer

. . . Johnson

M. A.

(2002). Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. American Journal of psychiatry, 159, 36-42.

Chae

P. K.

Jung

H. O.

Noh

K. S.

(2001). Attention deficit hyperactivity disorder in Korean juvenile delinquents. Adolescence, 36, 707-725.

Cox

E. D.

Smith

M. A.

Brown

R. L.

Fitzpatrick

M. A.

(2007). Effect of gender and visit length on participation in pediatric visits. Patient Education and Counseling, 65, 320-328.

D’Agostino

R. B.

Jr. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics in medicine, 17, 2265-2281.

Elia

Ambrosini

Berrettini

(2008). ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. Child and Adolescent Psychiatry and Mental Health, 2, 15.

10.

Ercan

E. S.

Varan

Deniz

(2005). Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: A preliminary report. Journal of Child and Adolescent Psychopharmacology, 15, 203-219.

11.

Erol

Simsek

Oner

Munir

(2008). Epidemiology of attention problems among Turkish children and adolescents: A national study. Journal Attention Disorders, 11, 538-545.

12.

Erşan

E. E.

Doğan

Sumer

(2004).The distribution of symptoms of attention-deficit/hyperactivity disorder and oppositional defiant disorder in school age children in Turkey. European child and Adolescent Psychiatry, 13, 354-361.

13.

Escobar

Soutullo

C. A.

Hervas

Gastaminza

Polavieja

Gilaberte

(2005). Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics, 116, e364-e369.

14.

Faraone

S. V.

Sergeant

Gillberg

Biederman

(2003). The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry, 2, 104-113.

15.

Faries

Ascher-Svanum

Belger

(2007). Analysis of treatment effectiveness in longitudinal observational data. Journal of Biopharmaceutical Statistics, 17, 809-826.

16.

Froehlich

T. E.

Lanphear

B. P.

Epstein

J. N.

Barbaresi

W. J.

Katusic

S. K.

Kahn

R. S.

(2007). Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Archives of Pediatrics and Adolescent Medicine, 161, 857-864.

17.

Gadow

K. D.

Sprafkin

(1997). Adolescent Symptom Inventory 4, Screening Manual. Stony Brook, NY: Checkmate Plus.

18.

Gadow

K. D.

Sprafkin

(2002). Childhood Symptom Inventory-4 Norms/Manual. Stony Brook, NY: Checkmate Plus.

19.

Gadow

K. D.

Nolan

E. E.

Litcher

Carlson

G. A.

Panina

Golovakha

. . . Bromet

E. J.

(2000). Comparison of attention-deficit/hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 1520-1527.

20.

Gau

S. S.

Chen

S. J.

Chou

W. J.

Cheng

Tang

C. S.

Chang

H. L.

. . . Huang

Y. S.

(2008). National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry, 69, 131-140.

21.

Gau

S. S.

Chong

M. Y.

Chen

T. H.

Cheng

A. T.

(2005). A 3-year panel study of mental disorders among adolescents in Taiwan. American Journal of Psychiatry, 162, 1344-1350.

22.

Gaub

Carlson

C. L.

(1997). Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. Journal of Abnormal Child Psychology, 25, 103-111.

23.

Goldman

L. S.

Genel

Bezman

R. J.

Slanetz

P. J.

(1998). Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association, 279, 1100-1107.

24.

Graetz

B.W.

Sawyer

M. G.

Hazell

P. L.

Arney

Baghurst

(2001). Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1410-1417.

25.

Guy

(1976). ECDEU assessment manual for psychopharmacology (Revised). Bethesda, MD: U.S. Department of Health, Education and Welfare.

26.

Hechtman

(2000). Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 481-498.

27.

Hirfanoğlu

Soysal

A. S.

Gücüyener

Cansu

Serdaroğlu

(2008). A study of perceptions, attitudes, and level of knowledge among pediatricians towards attention-deficit/hyperactivity disorder. Turkish Journal of pediatrics, 50, 160-166.

28.

Klassen

A. F.

Miller

Fine

(2004). Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics, 114, e541-e547.

29.

Leung

P. W.

Luk

S. L.

T. P.

Taylor

Mak

F. L.

Bacon-Shone

(1996). The diagnosis and prevalence of hyperactivity in Chinese schoolboys. British Journal of Psychiatry, 168, 486-496.

30.

Mann

E. M.

Ikeda

Mueller

C. W.

Takahashi

Tao

K. T.

Humris

. . . Chin

(1992). Cross-cultural differences in rating hyperactive-disruptive behaviors in children. American Journal of Psychiatry, 149, 1539-1542.

31.

Martényi

Treuer

Gau

S. F.

Hong

S. D.

Palaczky

Suba

. . . Harrison

(2009). Attention-deficit/hyperactivity disorder: Diagnosis, comorbidities, treatment patterns and quality of life in a paediatric population in Central and Eastern Europe and Asia. Journal of Child and Adolescent Psychopharmacology, 19, 363-376.

32.

Nolan

E. E.

Gadow

K. D.

Sprafkin

(2001). Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. Journal of Child and Adolescent Psychopharmacology, 40, 241-249.

33.

Pliszka

S. R.

(2007). Pharmacologic treatment of attention-deficit/hyperactivity disorder: Efficacy, safety and mechanisms of action. Neuropsychology Review, 17, 61-72.

34.

Polanczyk

de Lima

M. S.

Horta

B. L.

Biederman

Rohde

L. A.

(2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942-948.

35.

Prasad

Harpin

Poole

Zeitlin

Jamdar

Puvanendran

(2007). The SUNBEAM Study Group: A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Current Medical Research and Opinion, 23, 379-394.

36.

Prince

J. B.

(2006). Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: Update on new stimulant preparations, atomoxetine, and novel treatments. Child and Adolescent Psychiatric Clinics of North America, 15, 13-50.

37.

Quinn

Wigal

(2004). Perceptions of girls and ADHD: Results from a national survey. Medscape General Medicine, 6, 2.

38.

Ralston

S. J.

Lorenzo

M. J.

(2004). ADORE study group—Attention-deficit hyperactivity disorder observational research in Europe. European Child and Adolescent Psychiatry, 13 (Suppl 1: I36-42), I36-I42.

39.

Riley

A. W

Forrest

C. B.

Starfield

Rebok

G. W.

Robertson

J. A.

Green

B. F.

(2004). The parent report form of the CHIP-Child Edition: Reliability and validity. Medical Care, 42, 210-220.

40.

Riley

A. W.

Lyman

L. M.

Spiel

Dopfner

Lorenzo

M. J.

Ralston

S. J.

, ADORE Study Group. (2007). The family strain index (FSI). Reliability, validity, and factor structure of a brief questionnaire for families of children with ADHD. European Child and Adolescent Psychiatry, 16, I/72-I/78.

41.

Riley

A. W.

Robertson

Forrest

C. B.

Green

Rebok

Starfield

(2001). Manual for the child health and illness profile—Child edition (CHIP-CE). Baltimore, MD: Johns Hopkins University.

42.

Riley

A. W.

Spiel

Coghillk

Dopfner

Falissard

Lorenzo

M. J.

. . . Ralston

S. J.

(2006). ADORE study group: Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. European Child and Adolescent Psychiatry, 15, S38-S45.

43.

Swanson

J. M.

Sergeant

J. A.

Taylor

Sonuga-Barke

E. J.

Jensen

P. S.

Cantwell

D. P.

(1998). Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet, 351, 429-433.

44.

Takahashi

Miyawaki

Suzuki

Mamoto

Matsushima

Tsuji

. . . Kiriike

(2007). Hyperactivity and comorbidity in Japanese children with attention-deficit/hyperactivity disorder. Psychiatry and Clinical Neurosciences, 61, 255-262.

45.

The MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder multimodal treatment study of children with ADHD. Archives of General Psychiatry, 56, 1073-1086.

46.

Topolski

T. D.

Edwards

T. C.

Patrick

D. L.

Varley

Way

M. E.

Buesching

D. P.

(2004). Quality of life of adolescent males with attention-deficit hyperactivity disorder. Journal of Attention Disorders, 7, 163-173.

47.

Wang

Y. C.

Chong

M. Y.

Chou

W. J.

Yang

(1993). Prevalence of attention deficit hyperactivity disorder in primary school children in Taiwan. Journal of the Formosan Medical Association, 92, 133-138.

48.

World Health Organization. (1993). The ICD-10 classification of mental and behavioural disorders: Clinical description and diagnostic guidelines 1992. Diagnostic Criteria for Research 1993. Geneva, WHO.